nach oben

Current Bladder Dysfunction Reports

Erschienen in:

13.11.2020 | Reconstructed Bladder Function & Dysfunction (M Kaufman, Section Editor)

Antibiotic Prophylaxis in Pelvic Floor Surgery

verfasst von: Gregory M. Kunkel, Joshua A. Cohn

Erschienen in: Current Bladder Dysfunction Reports | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The goal of this review is to summarize the current recommendations and evidence for the use of antibiotic prophylaxis in pelvic floor surgery. We provide a historical perspective on antimicrobial prophylaxis, review bacteria associated with pelvic floor surgery by site, and current antimicrobial prophylaxis recommendations from the American Urological Association (AUA) and American College of Obstetrics and Gynecology (ACOG).

Recent Findings

ACOG published updated recommendations for perioperative prophylaxis in June 2018 and the AUA in June 2019. There has been a complete de-emphasis on the use of fluoroquinolones; the preferred antimicrobials, when indicated, are first and second generation Cephalosporins alone for nearly all pelvic floor procedures via a vaginal or abdominal approach. Aside from allergy considerations, exceptions include reconstruction with use of large bowel, for which additional anaerobic coverage and mechanical and antibiotic bowel prep is recommended, and for select diagnostic and therapeutic procedures of the lower urinary tract, for which trimethoprim-sulfamethoxazole is recommended.

Summary

Pelvic floor surgery is unique due to its variable surgical approaches and the range of potential infectious sources to be considered (i.e., the skin, vagina, bladder, intestine). Urinary tract infection is the most common infectious complication across nearly all procedures, although its prevention is not simply related to antibiotic selection and duration. Antibiotic stewardship calls for judicious use, including non-use when risks are low. Although updated societal guidelines provide the foundation on which most perioperative antimicrobial recommendations should be based, surgeons must consider patient-specific factors (e.g., multidrug -resistant bacteriuria) and local antibiograms. Input from colleagues in pharmacy and infectious diseases may optimize antibiotic selection, dosing, and duration, particularly when non-guideline antibiosis appears to be indicated.

Surgical Site Infection (SSI) event. In: Network NHS, Prevention CfDCa, editors. Online2017.

•• Lightner DJ, Wymer K, Sanchez J, Kavoussi L. Best practice statement on urologic procedures and antimicrobial prophylaxis. J Urol. 2020;203(2):351–6. https://doi.org/10.1097/JU.0000000000000509This reference served as the primary resource for this review for antibiotic prophylaxis evidence and recommendations.CrossRefPubMed

Lister J. On the antiseptic principle in the practice of surgery. Br Med J. 1867;2(351):246–8. https://doi.org/10.1136/bmj.2.351.246.CrossRefPubMedPubMedCentral

• Chodak GW, Plaut ME. Use of systemic antibiotics for prophylaxis in surgery: a critical review. Arch Surg. 1977;112(3):326–34. https://doi.org/10.1001/archsurg.1977.01370030098018This seminal reference provided the basis for current antibiotic prophylaxis rationale.CrossRefPubMed

Black JD, de Haydu C, Fan L, Sheth SS. Surgical site infections in gynecology. Obstet Gynecol Surv. 2014;69(8):501–10. https://doi.org/10.1097/OGX.0000000000000102.CrossRefPubMed

Pop-Vicas A, Musuuza JS, Schmitz M, Al-Niaimi A, Safdar N. Incidence and risk factors for surgical site infection post-hysterectomy in a tertiary care center. Am J Infect Control. 2017;45(3):284–7. https://doi.org/10.1016/j.ajic.2016.10.008.CrossRefPubMed

Haraway AM, Clemens JQ, He C, Stroup C, Atiemo HO, Cameron AP. Differences in sacral neuromodulation device infection rates based on preoperative antibiotic selection. Int Urogynecol J. 2013;24(12):2081–5. https://doi.org/10.1007/s00192-013-2121-z.CrossRefPubMed

Myer ENB, Petrikovets A, Slocum PD, Lee TG, Carter-Brooks CM, Noor N et al. Risk factors for explantation due to infection after sacral neuromodulation: a multicenter retrospective case-control study. Am J Obstet Gynecol. 2018;219(1):78 e1- e9. doi:https://doi.org/10.1016/j.ajog.2018.04.005.

Brueseke T, Livingston B, Warda H, Osann K, Noblett K. Risk factors for surgical site infection in patients undergoing sacral nerve modulation therapy. Female Pelvic Med Reconstr Surg. 2015;21(4):198–204. https://doi.org/10.1097/SPV.0000000000000183.CrossRefPubMed

10.

Uppal S, Harris J, Al-Niaimi A, Swenson CW, Pearlman MD, Reynolds RK, et al. Prophylactic antibiotic choice and risk of surgical site infection after hysterectomy. Obstet Gynecol. 2016;127(2):321–9. https://doi.org/10.1097/AOG.0000000000001245.CrossRefPubMedPubMedCentral

11.

Sanaee MS, Hutcheon JA, Larouche M, Brown HL, Lee T, Geoffrion R. Urinary tract infection prevention after midurethral slings in pelvic floor reconstructive surgery: a systematic review and meta-analysis. Acta Obstet Gynecol Scand. 2019;98:1514–22. https://doi.org/10.1111/aogs.13661.CrossRefPubMed

12.

Vigil HR, Mallick R, Nitti VW, Lavallee LT, Breau RH, Hickling DR. Risk factors for urinary tract infection following mid urethral sling surgery. J Urol. 2017;197(5):1268–73. https://doi.org/10.1016/j.juro.2016.12.093.CrossRefPubMed

13.

Foxman B, Cronenwett AE, Spino C, Berger MB, Morgan DM. Cranberry juice capsules and urinary tract infection after surgery: results of a randomized trial. Am J Obstet Gynecol. 2015;213(2):194 e1–8. doi:https://doi.org/10.1016/j.ajog.2015.04.003.

14.

Chung CP, Kuehl TJ, Harris SK, McBride MM, Larsen WI, Yandell PM, et al. Incidence and risk factors of postoperative urinary tract infection after uterosacral ligament suspension. Int Urogynecol J. 2012;23(7):947–50. https://doi.org/10.1007/s00192-012-1709-z.CrossRefPubMed

15.

Gehrich AP, Lustik MB, Mehr AA, Patzwald JR. Risk of postoperative urinary tract infections following midurethral sling operations in women undergoing hysterectomy. Int Urogynecol J. 2016;27(3):483–90. https://doi.org/10.1007/s00192-015-2861-z.CrossRefPubMed

16.

Fok CS, McKinley K, Mueller ER, Kenton K, Schreckenberger P, Wolfe A, et al. Day of surgery urine cultures identify urogynecologic patients at increased risk for postoperative urinary tract infection. J Urol. 2013;189(5):1721–4. https://doi.org/10.1016/j.juro.2012.11.167.CrossRefPubMed

17.

Lachiewicz MP, Moulton LJ, Jaiyeoba O. Pelvic surgical site infections in gynecologic surgery. Infect Dis Obstet Gynecol. 2015;2015:614950–8. https://doi.org/10.1155/2015/614950.CrossRefPubMedPubMedCentral

18.

Steiner HL, Strand EA. Surgical-site infection in gynecologic surgery: pathophysiology and prevention. Am J Obstet Gynecol. 2017;217(2):121–8. https://doi.org/10.1016/j.ajog.2017.02.014.CrossRefPubMed

19.

Goede WJ, Lovely JK, Thompson RL, Cima RR. Assessment of prophylactic antibiotic use in patients with surgical site infections. Hosp Pharm. 2013;48(7):560–7. https://doi.org/10.1310/hpj4807-560.CrossRefPubMedPubMedCentral

20.

•z Shapiro R, Laignel R, Kowcheck C, White V, Hashmi M. Modifying pre-operative antibiotic overuse in gynecologic surgery. Int J Health Care Qual Assur. 2018;31(5):400–5. https://doi.org/10.1108/IJHCQA-04-2017-0066This reference classified non-adherence to antibiotic prophylaxis recommendations.

21.

Wright JD, Hassan K, Ananth CV, Herzog TJ, Lewin SN, Burke WM, et al. Use of guideline-based antibiotic prophylaxis in women undergoing gynecologic surgery. Obstet Gynecol. 2013;122(6):1145–53. https://doi.org/10.1097/AOG.0b013e3182a8a36a.CrossRefPubMedPubMedCentral

22.

Joyce J, Langsjoen J, Sharadin C, Kuehl TJ, Larsen WI. Inappropriate use of antibiotics in patients undergoing gynecologic surgery. Proc (Bayl Univ Med Cent). 2017;30(1):30–2. https://doi.org/10.1080/08998280.2017.11929518.CrossRef

23.

Turner LC, Kantartzis K, Lowder JL, Shepherd JP. The effect of age on complications in women undergoing minimally invasive sacral colpopexy. Int Urogynecol J. 2014;25(9):1251–6. https://doi.org/10.1007/s00192-014-2391-0.CrossRefPubMed

24.

Kantartzis K, Sutkin G, Winger D, Wang L, Shepherd J. Introduction of laparoscopic sacral colpopexy to a fellowship training program. Int Urogynecol J. 2013;24(11):1877–81. https://doi.org/10.1007/s00192-013-2085-z.CrossRefPubMedPubMedCentral

25.

Deffieux X, Letouzey V, Savary D, Sentilhes L, Agostini A, Mares P, et al. Prevention of complications related to the use of prosthetic meshes in prolapse surgery: guidelines for clinical practice. Eur J Obstet Gynecol Reprod Biol. 2012;165(2):170–80. https://doi.org/10.1016/j.ejogrb.2012.09.001.CrossRefPubMed

26.

Mangir N, Roman S, Chapple CR, MacNeil S. Complications related to use of mesh implants in surgical treatment of stress urinary incontinence and pelvic organ prolapse: infection or inflammation? World J Urol. 2020;38(1):73–80. https://doi.org/10.1007/s00345-019-02679-w.CrossRefPubMed

27.

^•• ACOG Practice Bulletin No. 195: Prevention of infection after gynecologic procedures. Obstet Gynecol. 2018;131(6):e172–e89. https://doi.org/10.1097/AOG.0000000000002670This reference provided antibiotic recommendations and evidence for a number of procedures.

28.

Theofanides MC, Sui W, Sebesta EM, Onyeji I, Matulay JT, Chung DE. Vesicovaginal fistulas in the developed world: an analysis of disease characteristics, treatments, and complications of surgical repair using the ACS-NSQIP database. Neurourol Urodyn. 2017;36(6):1622–8. https://doi.org/10.1002/nau.23167.CrossRefPubMed

29.

Morhason-Bello IO, Ojengbede OA, Adedokun BO, Okunlola MA, Oladokun A. Uncomplicated midvaginal vesico-vaginal fistula repair in Ibadan: a comparison of the abdominal and vaginal routes. Ann Ib Postgrad Med. 2008;6(2):39–43. https://doi.org/10.4314/aipm.v6i2.64051.CrossRefPubMedPubMedCentral

30.

Abreu AL, Chopra S, Dharmaraja A, Djaladat H, Aron M, Ukimura O, et al. Robot-assisted bladder diverticulectomy. J Endourol. 2014;28(10):1159–64. https://doi.org/10.1089/end.2014.0149.CrossRefPubMed

31.

Du K, Mulroy EE, Wallis MC, Zhang C, Presson AP, Cartwright PC. Enterocystoplasty 30-day outcomes from National Surgical Quality Improvement Program Pediatric 2012. J Pediatr Surg. 2015;50(9):1535–9. https://doi.org/10.1016/j.jpedsurg.2015.04.009.CrossRefPubMed

32.

Wu SY, Kuo HC. A real-world experience with augmentation enterocystoplasty-high patient satisfaction with high complication rates. Neurourol Urodyn. 2018;37(2):744–50. https://doi.org/10.1002/nau.23339.CrossRefPubMed

33.

Osborn DJ, Dmochowski RR, Kaufman MR, Milam DF, Mock S, Reynolds WS. Cystectomy with urinary diversion for benign disease: indications and outcomes. Urology. 2014;83(6):1433–7. https://doi.org/10.1016/j.urology.2014.02.030.CrossRefPubMed

34.

Cohn JA, Large MC, Richards KA, Steinberg GD, Bales GT. Cystectomy and urinary diversion as management of treatment-refractory benign disease: the impact of preoperative urological conditions on perioperative outcomes. Int J Urol. 2014;21(4):382–6. https://doi.org/10.1111/iju.12284.CrossRefPubMed

35.

Pariser JJ, Anderson BB, Pearce SM, Han Z, Rodriguez JA, 3rd, Landon E et al. The effect of broader, directed antimicrobial prophylaxis including fungal coverage on perioperative infectious complications after radical cystectomy. Urol Oncol. 2016;34(3):121 e9–14. doi:https://doi.org/10.1016/j.urolonc.2015.10.007.

36.

Togan T, Azap OK, Durukan E, Arslan H. The prevalence, etiologic agents and risk factors for urinary tract infection among spinal cord injury patients. Jundishapur J Microbiol. 2014;7(1):e8905. https://doi.org/10.5812/jjm.8905.CrossRefPubMedPubMedCentral

37.

Yoon SB, Lee BS, Lee KD, Hwang SI, Lee HJ, Han ZA. Comparison of bacterial strains and antibiotic susceptibilities in urinary isolates of spinal cord injury patients from the community and hospital. Spinal Cord. 2014;52(4):298–301. https://doi.org/10.1038/sc.2014.10.CrossRefPubMed

38.

Nguyen JN, Yang ST. Perioperative outcomes after robotic versus vaginal surgery for pelvic organ prolapse. J Robot Surg. 2020;14(3):415–21. https://doi.org/10.1007/s11701-019-01006-0.CrossRefPubMed

39.

Altman D, Falconer C. Perioperative morbidity using transvaginal mesh in pelvic organ prolapse repair. Obstet Gynecol. 2007;109(2 Pt 1):303–8. https://doi.org/10.1097/01.AOG.0000250970.23128.63.CrossRefPubMed

40.

Hill AJ, Walters MD, Unger CA. Perioperative adverse events associated with colpocleisis for uterovaginal and posthysterectomy vaginal vault prolapse. Am J Obstet Gynecol. 2016;214(4):501 e1- e6. doi:https://doi.org/10.1016/j.ajog.2015.10.921.

41.

Raup VT, Hess DS, Hanske J, Schmid M, Varda B, Das A, et al. Patient characteristics and perioperative outcomes of female urethral diverticulectomy: analysis of a multi-institutional prospective database. Urology. 2015;86(4):712–5. https://doi.org/10.1016/j.urology.2015.07.007.CrossRefPubMed

42.

Unger CA, Walters MD, Ridgeway B, Jelovsek JE, Barber MD, Paraiso MF. Incidence of adverse events after uterosacral colpopexy for uterovaginal and posthysterectomy vault prolapse. Am J Obstet Gynecol. 2015;212(5):603 e1–7. doi:https://doi.org/10.1016/j.ajog.2014.11.034.

43.

Sori DA, Azale AW, Gemeda DH. Characteristics and repair outcome of patients with Vesicovaginal fistula managed in Jimma University teaching Hospital, Ethiopia. BMC Urol 2016;16(1):41. doi:https://doi.org/10.1186/s12894-016-0152-8.

44.

Eilber KS, Kavaler E, Rodriguez LV, Rosenblum N, Raz S. Ten-year experience with transvaginal vesicovaginal fistula repair using tissue interposition. J Urol. 2003;169(3):1033–6. https://doi.org/10.1097/01.ju.0000049723.57485.e7.CrossRefPubMed

45.

Stanford EJ, Paraiso MF. A comprehensive review of suburethral sling procedure complications. J Minim Invasive Gynecol. 2008;15(2):132–45. https://doi.org/10.1016/j.jmig.2007.11.004.CrossRefPubMed

46.

Swartz M, Ching C, Gill B, Li J, Rackley R, Vasavada S, et al. Risk of infection after midurethral synthetic sling surgery: are postoperative antibiotics necessary? Urology. 2010;75(6):1305–8. https://doi.org/10.1016/j.urology.2009.11.081.CrossRefPubMed

47.

Doganay M, Cavkaytar S, Kokanali MK, Ozer I, Aksakal OS, Erkaya S. Risk factors for postoperative urinary tract infection following midurethral sling procedures. Eur J Obstet Gynecol Reprod Biol. 2017;211:74–7. https://doi.org/10.1016/j.ejogrb.2017.02.006.CrossRefPubMed

48.

Ingber MS, Vasavada SP, Firoozi F, Goldman HB. Incidence of perioperative urinary tract infection after single-dose antibiotic therapy for midurethal slings. Urology. 2010;76(4):830–4. https://doi.org/10.1016/j.urology.2010.05.038.CrossRefPubMed

49.

Richter HE, Albo ME, Zyczynski HM, Kenton K, Norton PA, Sirls LT, Kraus SR, Chai TC, Lemack GE, Dandreo KJ, Varner RE, Menefee S, Ghetti C, Brubaker L, Nygaard I, Khandwala S, Rozanski TA, Johnson H, Schaffer J, Stoddard AM, Holley RL, Nager CW, Moalli P, Mueller E, Arisco AM, Corton M, Tennstedt S, Chang TD, Gormley EA, Litman HJ, Urinary Incontinence Treatment Network. Retropubic versus transobturator midurethral slings for stress incontinence. N Engl J Med 2010;362(22):2066–2076. doi:https://doi.org/10.1056/NEJMoa0912658.

50.

Harmanli O, Hong EK, Rubin R, Jones KA, Boyer RL, Metz S. Is antibiotic prophylaxis necessary for midurethral sling procedures? A series of 174 cases without preoperative antibiotics. Int Urogynecol J. 2012;23(5):621–3. https://doi.org/10.1007/s00192-011-1624-8.CrossRefPubMed

51.

Brubaker L, Norton PA, Albo ME, Chai TC, Dandreo KJ, Lloyd KL et al. Adverse events over two years after retropubic or transobturator midurethral sling surgery: findings from the Trial of Midurethral Slings (TOMUS) study. Am J Obstet Gynecol. 2011;205(5):498 e1–6. doi:https://doi.org/10.1016/j.ajog.2011.07.011.

52.

•• Clennon EK, Martinez Acevedo A, Sajadi KP. Safety and effectiveness of zero antimicrobial prophylaxis protocol for outpatient cystourethroscopy. BJU Int. 2019;123(5A):E29–33. https://doi.org/10.1111/bju.14662This reference emphasized the need for antibiotic stewardship and the efficacy of doing so.

53.

Garcia-Perdomo HA, Lopez H, Carbonell J, Castillo D, Catano JG, Seron P. Efficacy of antibiotic prophylaxis in patients undergoing cystoscopy: a randomized clinical trial. World J Urol. 2013;31(6):1433–9. https://doi.org/10.1007/s00345-013-1034-2.CrossRefPubMed

54.

Herr HW. Should antibiotics be given prior to outpatient cystoscopy? A plea to urologists to practice antibiotic stewardship. Eur Urol. 2014;65(4):839–42. https://doi.org/10.1016/j.eururo.2013.08.054.CrossRefPubMed

55.

•• Gregg JR, Bhalla RG, Cook JP, Kang C, Dmochowski R, Talbot TR, et al. An evidence-based protocol for antibiotic use prior to cystoscopy decreases antibiotic use without impacting post-procedural symptomatic urinary tract infection rates. J Urol. 2018;199(4):1004–10. https://doi.org/10.1016/j.juro.2017.10.038This reference emphasized the need for antibiotic stewardship and the efficacy of doing so.

56.

•• Cameron AP, Campeau L, Brucker BM, Clemens JQ, Bales GT, Albo ME, et al. Best practice policy statement on urodynamic antibiotic prophylaxis in the non-index patient. Neurourol Urodyn. 2017;36(4):915–26. https://doi.org/10.1002/nau.23253This reference provided antibiotic recommendations and evidence for select procedures.

57.

Yokoyama M, Fujii Y, Yoshida S, Saito K, Koga F, Masuda H, et al. Discarding antimicrobial prophylaxis for transurethral resection of bladder tumor: a feasibility study. Int J Urol. 2009;16(1):61–3. https://doi.org/10.1111/j.1442-2042.2008.02188.x.CrossRefPubMed

58.

Ibrahim AI, Rashid M. Comparison of local povidone-iodine antisepsis with parenteral antibacterial prophylaxis for prevention of infective complications of TURP: a prospective randomized controlled study. Eur Urol. 2002;41(3):250–6. https://doi.org/10.1016/s0302-2838(02)00013-1.CrossRefPubMed

59.

May A, Broggi E, Lorphelin H, Tabchouri N, Giretti G, Pereira H, et al. Comparison of the risk of postoperative infection between transurethral vaporesection and transurethral resection of the prostate. Lasers Surg Med. 2014;46(5):405–11. https://doi.org/10.1002/lsm.22240.CrossRefPubMed

60.

Mouttalib S, Khan S, Castel-Lacanal E, Guillotreau J, De Boissezon X, Malavaud B, et al. Risk of urinary tract infection after detrusor botulinum toxin A injections for refractory neurogenic detrusor overactivity in patients with no antibiotic treatment. BJU Int. 2010;106(11):1677–80. https://doi.org/10.1111/j.1464-410X.2010.09435.x.CrossRefPubMed

61.

Khan MH, Baldo O, Koenig P, Shaikh N. Use of prophylactic antibiotics for intra-vesicle Botox(R) injection. Neurourol Urodyn. 2017;36(3):828. https://doi.org/10.1002/nau.23034.CrossRefPubMed

62.

Nitti VW, Dmochowski R, Herschorn S, Sand P, Thompson C, Nardo C, et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol. 2013;189(6):2186–93. https://doi.org/10.1016/j.juro.2012.12.022.CrossRefPubMed

63.

Houman J, Moradzadeh A, Patel DN, Asanad K, Anger JT, Eilber KS. What is the ideal antibiotic prophylaxis for intravesically administered Botox injection? A comparison of two different regimens. Int Urogynecol J. 2019;30(5):701–4. https://doi.org/10.1007/s00192-018-3721-4.CrossRefPubMed

Titel: Antibiotic Prophylaxis in Pelvic Floor Surgery
verfasst von: Gregory M. Kunkel
Joshua A. Cohn
Publikationsdatum: 13.11.2020
Verlag: Springer US
Erschienen in: Current Bladder Dysfunction Reports / Ausgabe 4/2020
Print ISSN: 1931-7212
Elektronische ISSN: 1931-7220
DOI: https://doi.org/10.1007/s11884-020-00601-4

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

Stufenschema weist Prostatakarzinom zuverlässig nach

22.04.2024 Prostatakarzinom Nachrichten

Erst PSA-Test, dann Kallikrein-Score, schließlich MRT und Biopsie – ein vierstufiges Screening-Schema kann die Zahl der unnötigen Prostatabiopsien erheblich reduzieren: Die Hälfte der Männer, die in einer finnischen Studie eine Biopsie benötigten, hatte einen hochgradigen Tumor.

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

20.04.2024 EAU 2024 Kongressbericht

Beim chronischen Harnwegsinfekt bei Frauen wird bisher meist eine Antibiotikaprophylaxe eingesetzt. Angesichts der zunehmenden Antibiotikaresistenz erweist sich das Antiseptikum Methenamin-Hippurat als vielversprechende Alternative, so die Auswertung einer randomisierten kontrollierten Studie.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2020

Urodynamics for the “Failed” Midurethral Sling

The Role of Organizations like IVUmed in Developing Centers of Excellence

Vaginal Yeast Infection

Cost-Effectiveness and Economic Benefits of Volunteerism